Treatment Algorithm for Follicular Lymphoma

Opinion
Video

Pallawi Torka, MD, joins the Oncology Brothers to discuss patient workup and treatment practices in follicular lymphoma, highlighting the PRIMA study and the role of maintenance therapy.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 12th 2025
Article
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
September 12th 2025
Podcast
The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Mosunetuzumab Exhibits Meaningful Responses in Untreated MZL

Roman Fabbricatore
September 12th 2025
Article
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
September 12th 2025
Podcast
This was the first trial for patients with late-stage WM to show the potential for complete responses with a chemotherapy-free immunotherapy.

Novel CD19 CAR-NK Therapy Yields Responses in Waldenstrom Macroglobulinemia

Tim Cortese
September 12th 2025
Article
Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Considerations for CAR T Use Across Large B-Cell Lymphoma Variants

Roman Fabbricatore
September 12th 2025
Article